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Dysregulation of the mTOR Pathway 
Secondary to Mutations or a Hostile 
Microenvironment Contributes to 
Cancer and Poor Wound Healing
Richard A.F. Clark1 and Michelle Pavlis2
Either heredity mutations or adverse microenvironment conditions may result 
in dysregulation of the mammalian target of the rapamycin (mTOR) pathway. 
The former lead to clinical syndromes such as tuberous sclerosis, Peutz-
Jeghers syndrome, and Cowden’s disease, which are characterized  by hamar-
tomatous growth or cancer.  The latter can be associated with poor wound 
healing as described by Goren et al. (2009, this issue).
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The mammalian target of the rapa mycin 
(mTOR) pathway and its upstream 
regulators are essential for normal cell 
survival, growth, and differentiation. 
Dysregulation of this pathway can lead 
to premature cell death, poor cell and 
tissue growth, or uncontrolled tissue 
growth. Goren et al. (2009, this issue) 
report that Akt1 (also known as protein 
kinase B, or PKB), an upstream positive 
regulator of mTOR, is hypophosphory-
lated in the healing epidermis of wound-
ed, genetically diabetic ob/ob mice. The 
authors found that vascular endothelial 
growth factor (VEGF), which is associ-
ated with hypophosphorylation of Akt1 
and 4E-binding protein 1 (4E-BP1), a 
downstream effector of mTOR that reg-
ulates protein translation, failed to be 
synthesized in the epidermal cells at the 
margin of wounds in these mice. Using 
HaCat epidermal cell lines, the authors 
demonstrated that insulin stimulation of 
VEGF protein synthesis is dependent on 
Akt1 stimulation of mTOR and its down-
stream effector, 4E-BP1. The authors 
suggest that insulin contributes to VEGF 
release in wounded epidermis through 
an Akt1/mTOR/4E-BP1-mediated post-
transcriptional mechanism.
To appreciate the complexities of the 
mTOR pathway in metabolic hemosta-
sis and to link mutations in its upstream 
effectors to a number of hamartomatous 
genodermatoses—including tuberous 
sclerosis, Peutz–Jeghers syndrome, and 
Cowden’s disease, which are associ-
ated with a predisposition to cancer—it 
is necessary to review the overall path-
way. The active component of mTOR is a 
kinase found in two distinct complexes: 
mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). mTORC1 con-
sists of the mTOR catalytic subunit and 
raptor (regulatory-associated protein of 
mTOR), and it mediates activation of 
mTOR effectors such as ribosomal S6 
kinase (S6K). Instead of raptor, mTORC2 
contains rictor (rapamycin-insensitive 
companion of mTOR), and it regulates 
Akt that is upstream in the mTORC1 
pathway (Sabatini, 2006).
The mTORC1 pathway is critical for 
skin homeostasis (Calautti et al., 2005; 
Murayama et al., 2007; Pankow et al., 
2006) because it is the central controller 
for cell growth, metabolism, and angio-
genesis (Figure 1). It is regulated by the 
availability of glucose (Wullschleger 
et al., 2006), amino acids (not shown; 
Nobukuni et al., 2005), and growth fac-
tor signaling (Shaw and Cantley, 2006). 
A major negative regulator of mTORC1 
is the tuberous sclerosis complex protein 
1 and 2 (TSC1 and TSC2) (Figure 1). The 
importance of this negative regulation 
can be observed in patients with tuber-
ous sclerosis. Individuals who inherit 
autosomal dominant mutations in TSC1 
or TSC2 have a predisposition to mani-
fest numerous hamartomatous growths 
throughout the body during their life-
time, including facial angiofibromas, 
connective-tissue nevi (shagreen patch), 
and periungual and gingival fibromas. 
Details of the many possible presenta-
tions in such patients can be found in a 
recent review (Schwartz et al., 2007).
The TSC1/2 negative regulatory 
complex is activated by the adenosine 
monophosphate activated protein kinase 
(AMPK)/LKB1 (also known as serine/
threonine protein kinase 11) complex, 
which adds one phosphate to TSC2, 
thereby activating it (Sabatini, 2006). 
Activated TSC2, with its partner TSC1, 
then inhibits mTORC1. LKB1 is mutat-
ed in Peutz–Jeghers syndrome (Bauer 
and Stratakis, 2005); thus, the negative 
regulation of mTOR through TSC1/2 is 
abrogated, albeit indirectly. Patients with 
Peutz–Jeghers syndrome, like patients 
with tuberous sclerosis, develop hamar-
tomatous growths, but these occur 
mostly in the gastrointestinal tract, espe-
cially the small bowel. Patients are also 
at increased risk of developing cancer in 
many organs, with a lifetime risk as high 
as 90% (Amos et al., 2004).
Another negative regulator of 
mTORC1 that ultimately works through 
the TSC1/2 complex is the phosphatase 
and tensin homologue (PTEN) (Figure 1). 
PTEN is a lipid phosphatase that removes 
the phosphate from the D3 position of 
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the membrane lipid, phosphatidylinosi-
tol 3,4,5-triphosphate (PIP3) (Chow and 
Baker, 2006), thereby directly antagoniz-
ing the action of phosphatidylinositol 
3-kinase (PI3K), which phosphorylates 
the precursor membrane lipid, phos-
phatidylinositol 4,5-diphosphate, at 
D3 (Figure 2). PTEN is one of the most 
commonly lost signal transduction path-
way regulators in human cancer (Grant, 
2008). Individuals with mutations in 
the PTEN gene exhibit a variety of syn-
dromes, all of which are characterized 
in part by a predisposition to cancer. For 
example, patients with Cowden’s disease 
develop several types of hamartomatous 
growths, including trichilemmomas of 
the face, acral keratoses, papillomatous 
lesions of the skin and mucous mem-
branes, and intestinal polyps. The life-
time risk of breast and thyroid cancers in 
such patients is 25–50 and 10%, respec-
tively (Pilarski and Eng, 2004).
Other syndromes have been recog-
nized as being associated with PTEN 
mutations and lend support to the idea 
that such diseases are part of a PTEN–
hamartoma tumor syndrome spec-
trum (Marsh et al., 1999). For example, 
Bannayan–Riley–Ruvalcaba syndrome 
and Cowden’s disease are hamartoma 
syndromes that share clinical features 
and also have genetic overlap. In addi-
tion, some patients with Proteus-like 
syndrome—a disorder of patchy, or 
mosaic, progressive overgrowth that 
usually begins very early in infancy 
and can affect any part of the body—
have documented germline mutations 
in PTEN (Smith et al., 2002). However, 
some authors believe that a diagnosis of 
Proteus syndrome should be limited to 
patients with postzyotic somatic muta-
tions concordant with clinical manifesta-
tions of mosaicism, excluding cases that 
show a PTEN germline mutation from 
Proteus syndrome (Happle, 2007).
Normal cells in the presence of a con-
ducive microenvironment respond to 
growth factors with cell proliferation and 
growth. Proliferation is signaled through 
ras/MAPK pathways and growth is sig-
naled through the mTOR pathway (Shaw 
and Cantley, 2006). For the mTOR path-
way, cell stimulation with growth factors 
activates in sequence PI3K and Akt, which 
in turn inactivate the TSC1/TSC2 inhibitor 
complex, thereby releasing mTOR from 
Figure 2. mTORC1 pathway details. Growth factor receptor stimulation leads to PI3K activation, which 
phosphorylates PIP2 at the third position of the inositol ring, resulting in the creation of PIP3, a docking site 
for PDK1. Once docked, the constitutively active PDK1 can phosphorylate Akt, which in turn phosphorylates 
TSC2 at multiple sites that lead to the inactivation of the TSC1/TSC2 inhibitor complex, thereby releasing 
mTOR from inhibition. When cellular concentrations of glucose and ATP are low, the activated AMPK/LKB1 
complex adds a phosphate to TSC2, thus activating the TSC1/TSC2 complex, which inhibits mTOR. The 
TSC1/TSC2 complex is a GTPase-activating protein for Rheb. Upon conversion of GTP to GDP, Rheb loses 
its ability to bind mTORC1, which is necessary for mTORC1 activation. Activated mTOR stimulates protein 
synthesis, cell growth, and metabolism through phosphorylation of EEF2K, p70S6K, and 4E-BP1. 4E-BP1, 
eukaryotic initiation factor 4E binding protein 1; Akt, protein kinase B; AMPK, AMP-regulated protein kinase; 
ATP, adenosine triphosphate; Cap, capped mRNA; EEF2, eukaryotic elongation factor 2; EEF2K, eukaryotic 
elongation factor 2 kinase; EIF4E, eukaryotic initiation factor 4E; EIF4G, eukaryotic initiation factor 4G; 
GDP, guanidine diphosphate; GTP, guanidine triphosphate; LKB1, serine-threonine kinase 11; mTOR, 
mammalian target of rapamycin; p70S6K, ribosomal protein S6 kinase; PDK1, 3-phosphoinositide-dependent 
protein kinase; PI3K, phosphotidylinositol-3 kinase; PIP2, phosphatidylinositol 4,5-diphosphate; PIP3, 
phosphatidylinositol 3,4,5-triphosphate; Rheb, Ras homologue enriched in brain; TSC1 and TSC2, tuberous 
sclerosis complex 1 and 2; S6, ribosome S6. Modified with permission from Wouters and Koritzinsky, 2008.
Figure 1. mtorc1 pathway is the central controller of cell and tissue growth, metabolism, and 
angiogenesis. The mTOR complex is negatively regulated by the TSC1/TSC2 complex. When cellular 
concentrations of glucose and ATP are low, the AMPK/LKB1 complex activates TSC1/TSC2 complex, 
which inhibits mTOR. Growth factor receptor stimulation leads to PI3K activation, which in turn 
activates Akt through a series of steps indicated by the dashed arrow and shown in more detail in Figure 
2. Activated Akt phosphorylates TSC2 at multiple sites that lead to the inactivation of the TSC1/TSC2 
inhibitor complex, thereby releasing mTOR from inhibition. Akt, protein kinase B; AMPK, AMP-regulated 
protein kinase; ATP, adenosine triphosphate; LKB1, serine-threonine kinase 11; mTOR, mammalian target 
of rapamycin; TSC1 and TSC2, tuberous sclerosis complex 1 and 2; PI3K, phosphotidylinositol-3 kinase; 
PTEN, phosphatase and tensin homologue.
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inhibition. Activated mTOR stimulates the 
protein synthesis required for cell growth 
and metabolism through phosphorylation 
of 4E-BP1, eukaryotic elongation factor 2 
kinase, and ribosomal protein S6 kinase 
(p70S6K). These phosphorylated proteins 
assist mRNA translation to proteins by 
promoting capped mRNA to home to a 
ribosome, by enhancing translation elon-
gation, and by maintaining de novo syn-
thesis of S6 ribosomes, respectively (Shaw 
and Cantley, 2006).
Goren et al. (2009) focus on the abil-
ity of active mTORC1 complex to initi-
ate mRNA translation. Active mTORC1 
phosphorylates 4E-BP1, which inhibits its 
association with the cap-binding protein 
eukaryotic translation initiation factor 4E 
(EIF4E). The uncoupling of the 4E-BP1/
EIF4E complex allows the association 
of EIF4E with EIF4G and the initiation 
of cap-dependent translation (Hay and 
Sonenberg, 2004). It is clear from the 
authors’ data that epidermis at the wound 
edge in ob/ob mice demonstrated a pau-
city of VEGF protein from 1 to 5 days after 
wounding and that this defect could be 
reversed by leptin-mediated resolution 
of insulin resistance. It is also clear that 
HaCaT epidermal cell lines stimulated 
with insulin produced increased amounts 
of VEGF protein through an mTOR-
dependent, posttranslational process that 
correlated with increased 4E-BP1 phos-
phorylation. These in vitro data provide 
important and intriguing evidence about 
how the mTOR pathway could control 
VEGF protein production posttranslation-
ally and quite probably how this pathway 
could control the production of other pro-
teins by a similar mechanism. However, it 
is not clear that the paucity of VEGF in the 
nontreated ob/ob wounds was second-
ary to a posttranslational block, because 
VEGF mRNA was not measured in these 
wounds. Perhaps the authors will provide 
a follow-up to this very interesting story.
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A TR(I)P to Pruritus Research:  
Role of TRPV3 in Inflammation and Itch
Martin Steinhoff1 and Tamás Bíró2
Pruritus in eczema and other inflammatory skin diseases is an unsolved problem. 
Recent findings strongly indicate that histamine is not the only mediator of pruri-
tus. Subtypes of the transient receptor potential (TRP) ion channel superfamily are 
expressed by sensory nerves, keratinocytes, and certain leukocytes. Temperature, 
pH changes, and certain toxins activate TRPs. new evidence indicates that the 
vanilloid type 3 (TRPV3) channel is crucially involved in pruritic dermatitis, making 
it a good candidate for future therapy in skin inflammation and pruritus.
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old and new targets in pruritology
Pruritus (itch), perhaps the most com-
mon symptom in dermatology, is associ-
ated with numerous skin diseases, and 
it can be a lead or awkward symptom 
in inflammation and infection, as well 
as with certain tumors. No generally 
accepted treatment regimen exists for 
